Research & Science

Scientific Initiatives

Committed to addressing the needs in the melanoma research community.

Responding to needs in the field, the MRF has spearheaded several scientific initiatives including: the MRFBC (MRF Breakthrough Consortium) to foster multi-institutional translational research and the creation of CURE OM (Community United for Research and Education of Ocular Melanoma) to accelerate research and treatments focused on the most common malignant tumor of the eye and initiatives that focus on rare melanoma subsets such as pediatric and mucosal, and the conduct of various scientific meetings. The MRF has also established important partnerships with leading research organizations in order to advance its initiatives.

MRF Breakthrough Consortium 

The MRFBC is a national network of 20 centers of excellence in melanoma that collaborate to accelerate the research and development of the most promising therapies in melanoma treatment in order to deliver curative options to patients.

CURE Ocular Melanoma

Founded in 2011, CURE OM (the Community United for Research and Education of Ocular Melanoma) is the MRF’s initiative to increase awareness, education, and research  for ocular melanoma, while improving the lives of people affected by this disease. 

  • Get the latest updates on CURE OM’s VISION Registry, the patient-powered, patient-reported ocular melanoma registry launching in late 2020!

Pediatric & Mucosal Melanoma

The MRF has recently begun to focus its efforts on the rarer subsets of melanoma including pediatric and mucosal.

Scientific Meetings

The MRF convenes various scientific meetings each year either in response to an unmet need, as designated by our Scientific Advisory Committee (SAC) or to further the CURE OM, MRFBC, and/or other MRF Scientific Initiatives.

MRF Partnerships

The MRF has established important partnerships with leading research organizations including the Society for Melanoma Research (SMR), the Department of Defense (DoD), and the National Cancer Institute (NCI).